Target intelligence / Profile preview

Lipid A moiety of lipopolysaccharide (Lipid A)

Target
Lipid A
Molecular classification
Glycolipid, Structural lipid, Innate immune agonist, Other
01

Overview

Lipid A is a structurally conserved glycolipid comprising a β(1→6)-linked disaccharide of glucosamine, phosphorylated and acylated with multiple (usually six) fatty acids and phosphate groups[2][4][7]. It anchors lipopolysaccharide in the bacterial outer membrane and is responsible for most of LPS's toxic effects, triggering innate immune responses via TLR4 and related receptors[1][2][3]. Despite structural variability among bacteria, Lipid A universally contributes to membrane stability and pathogenesis, and has been extensively targeted for antibiotic and immunological intervention[3][5][8]. Modifying its acylation or phosphorylation state profoundly affects its immune activity and potential therapeutic use[3][7].

Other names
Lipid AEndotoxin core (occasionally, imprecise)LPS lipid domainGlycophospholipid moiety of lipopolysaccharide
02

Mechanism of action

Neutralization or antagonism of TLR4 activation (e.g., Eritoran); Disruption of outer membrane integrity, leading to bacterial death (e.g., polymyxins); Inhibition of biosynthetic enzymes (e.g., LpxC inhibitors); Immunomodulation as vaccine adjuvant (e.g., monophosphoryl lipid A)

03

Biological functions

Immune response activation (especially through TLR4 binding)Host-pathogen interactionOuter membrane structural integrity in Gram-negative bacteriaBarrier against environmental toxinsModulation of immune signaling (sometimes immunoadjuvant)
04

Disease associations

Infection (especially sepsis and Gram-negative septic shock)InflammationOther (e.g., modulated as a vaccine adjuvant)
05

Safety considerations

Direct targeting may cause strong inflammatory responses or pro-inflammatory cytokine storms, leading to septic shockModification to reduce toxicity (e.g., monophosphoryl lipid A) needed for clinical useAntibiotic resistance and membrane adaptation in bacteria can circumvent therapeutic intervention
06

Interacting drugs

Polymyxins (colistin, polymyxin B; disrupt Lipid A-LPS interactions)

3 more in the full profile.

07

Biomarkers

Circulating LPS/Lipid A for sepsis detectionTLR4 activity or downstream cytokine profiles

Beyond the preview

Go deeper on Lipid A moiety of lipopolysaccharide (Lipid A).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lipid A moiety of lipopolysaccharide (Lipid A).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call